Hormonal therapy in women, thromboembolic complications and laboratory characteristics of the hemostasis system for personalized solutions
https://doi.org/10.18705/2782-3806-2023-3-4-52-58
Abstract
The use of hormonal drugs for contraception and menopausal replacement therapy is widespread throughout the world. However, the use of these drugs is associated with an increased risk of thromboembolic complications (TEO). At present, it has been established that the most important cause of feasibility study is the initial, sometimes hidden, violations of the hemostasis system, predisposing to increased blood clotting and thrombosis. Their timely identification helps to personalize the use of the necessary hormonal therapy.
About the Authors
O. N. Startseva
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Startseva Olga N. - PhD (in Biol.), Biologist, Laboratory of Clinical Chemistry of the Department of Laboratory Diagnostics
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
Nikiforov Russian Center of Emergency and Radiation Medicine; Almazov National Medical Research Centre
Russian Federation
Vavilova Tatiana V.- Dr. Sc. (Med.), Professor, Head of Laboratory and Genetic Education Department
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
Nikiforov Russian Center of Emergency and Radiation Medicine; Almazov National Medical Research Centre
Russian Federation
Zybina Natalia N. - Dr. Sc. (in Biol.), Head of Department of clinical laboratory diagnostics
Academica Lebedeva str., 4/2, Saint Petersburg, 194044
References
1. Sotnikova L.S. Vozmozhnosti terapii i profilaktiki trombozov na fone gormonal'noi terapii v ginekologii / L. S. Sotnikova, E. V. Golubyatnikova // Ginekologiya. Endokrinologiya. 2017. № 9. S. 27-32.
2. Vereina N.K. Faktory riska venoznykh i arterial'nykh trombozov u molodykh zhenshchin vne beremennosti/ N. K. Vereina, T. V. Movchan, V. S. Chulkov // Aterotromboz. 2020. № 1. S. 18- 32.
3. Balandina A.N. Trombodinamika: novyi podkhod k diagnostike narushenii sistemy gemostaza / A. N. Balandina, E. N. Kol'tsova, A. M. Shibeko i dr.// Voprosy gematologii, onkologii i immunopatologii v pediatrii. 2018; 17 (4). S. 114-126.
4. Khamani N.M. Retrospektivnyi analiz faktorov riska tromboticheskikh oslozhnenii pri prieme kombinirovannykh oral'nykh kontratseptivov / N. M. Khamani, R. A. Saidova, I. V. Khamani i dr. // Akusherstvo i ginekologiya. 2019. № 6. S. 108-113.
5. Chen M. Contraception for women with medical problems / Chen M., Culwell K. // Glob. libr. women’s med., 2015 (ISSN: 1756-2228) 2015. https://doi.org/10.3843/GLOWM.10382.
6. Kruijf P De. A New Pharmacodynamic test to Evaluate effects of oral contraceptives on coagulation [abstract] / de Kruijf P, Naji S, Krijnen C, Jespersen J, Kluft C. A [abstract]. // Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-new-pharmacodynamic-test-to-evaluate-effects-of-oral-contraceptives-on-coagulation
7. Lidegaard O. Oral contraceptives and venous thromboembolism: a live-year national case-control studi / Lidegaard O., Edstrom B., Kreiner S. // Contraception. 2002; 65(3):187-96.
For citations:
Startseva O.N.,
Vavilova T.V.,
Zybina N.N.
Hormonal therapy in women, thromboembolic complications and laboratory characteristics of the hemostasis system for personalized solutions. Russian Journal for Personalized Medicine. 2023;3(4):52-58.
(In Russ.)
https://doi.org/10.18705/2782-3806-2023-3-4-52-58
Views:
183
Email this article 